Horizon Discovery partners with Amplycell on cell line optimisation

Horizon Discovery enters into R and D and licensing partnership with Amplycell for bioproduction cell line optimisation

UK applicators of gene editing technologies, Horizon Discovery, has entered into an R and D collaboration and license agreement with Belgian cell line developer, AmplyCell.

The collaboration is to evaluate the impact of AmplyCell’s BOOST cell line optimisation technology on Horizon’s parental GS (glutamine synthetase) null CHO K1 cell line.

AmplyCell's Cell Fitness Technologies, which include BOOST, consist of a four-stage process to optimise cell lines in terms of stability and productivity.

Cell lines can be stimulated using AmplyCell's Cell Fitness Technologies at any stage of cell line development or bioproduction (clone creation, RCB/DCB, MCB), without the need to change culture conditions.

Horizon’s CHO SOURCE platform comprises the industry standard GS selection system partnered with an expression vector and established culturing protocols.

We are hopeful that a successful evaluation will lead to incorporation of this methodology for all future bioprocessing cell lines.

Through the targeted application of genome editing, Horizon is constantly evolving this platform, generating a series of continually improved cell lines that further advance the bioproduction capability of CHO cells.

Before releasing its next generation of bioproduction cell lines, Horizon will evaluate the impact of Amplycell’s technology on the expression capability of their parental GS null CHO K1 cell line.

Horizon will have the non-exclusive worldwide rights to sublicense BOOSTed CHO-K1 cell lines to third parties.

Terry Pizzie, Head of Commercial, Horizon Discovery said: “We are hopeful that a successful evaluation of AmplyCell’s BOOST technology will lead to incorporation of this methodology for all future bioprocessing cell lines released by Horizon.”

Geoffrey Holsbeek, CEO of AmplyCell added: “AmplyCell has already demonstrated significant success in establishing biomanufacturing licensing deals around the globe and we are pleased to be able to support their drive to remain at the forefront of cell innovation.”

ll CHO K1 cell line. Horizon will have the non-exclusive worldwide rights to sublicense BOOSTed CHO-K1 cell lines to third parties. Terry Pizzie, Head of Commercial, Horizon Discovery said: “We are hopeful that a successful evaluation of AmplyCell’s BOOST technology will lead to incorporation of this methodology for all future bioprocessing cell lines released by Horizon, and look forward to creating a long term relationship with AmplyCell.” Geoffrey Holsbeek, CEO of AmplyCell added: “AmplyCell has already demonstrated significant success in establishing biomanufacturing licensing deals around the globe and we are pleased to be able to support their drive to remain at the forefront of cell innovation.”

Companies